JP7672012B2 - 相同染色体の一方に特異的なｄｎａ欠失を有する細胞を製造する方法 - Google Patents

相同染色体の一方に特異的なｄｎａ欠失を有する細胞を製造する方法 Download PDF

Info

Publication number
JP7672012B2
JP7672012B2 JP2023551836A JP2023551836A JP7672012B2 JP 7672012 B2 JP7672012 B2 JP 7672012B2 JP 2023551836 A JP2023551836 A JP 2023551836A JP 2023551836 A JP2023551836 A JP 2023551836A JP 7672012 B2 JP7672012 B2 JP 7672012B2
Authority
JP
Japan
Prior art keywords
chromosome
site
specific
dna
strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023551836A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023054573A1 (https=
Inventor
慎一郎 中田
亜希子 富田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of JPWO2023054573A1 publication Critical patent/JPWO2023054573A1/ja
Application granted granted Critical
Publication of JP7672012B2 publication Critical patent/JP7672012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023551836A 2021-09-30 2022-09-29 相同染色体の一方に特異的なｄｎａ欠失を有する細胞を製造する方法 Active JP7672012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021161312 2021-09-30
JP2021161312 2021-09-30
PCT/JP2022/036403 WO2023054573A1 (ja) 2021-09-30 2022-09-29 相同染色体の一方に特異的なｄｎａ欠失を有する細胞を製造する方法

Publications (2)

Publication Number Publication Date
JPWO2023054573A1 JPWO2023054573A1 (https=) 2023-04-06
JP7672012B2 true JP7672012B2 (ja) 2025-05-07

Family

ID=85782881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551836A Active JP7672012B2 (ja) 2021-09-30 2022-09-29 相同染色体の一方に特異的なｄｎａ欠失を有する細胞を製造する方法

Country Status (5)

Country Link
US (1) US20250129390A1 (https=)
EP (1) EP4410975A4 (https=)
JP (1) JP7672012B2 (https=)
CN (1) CN118043456A (https=)
WO (1) WO2023054573A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024204215A1 (ja) * 2023-03-28 2024-10-03 国立大学法人大阪大学 相同染色体の一方のＣｏｌ７ａ遺伝子に特異的なＤＮＡ欠失を有する細胞を製造する方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520317A (ja) 2013-05-29 2016-07-14 セレクティスＣｅｌｌｅｃｔｉｓ Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
JP2017535271A (ja) 2014-11-21 2017-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ガイドｒｎａのペアを使用したターゲティングによる遺伝子改変の方法及び組成物
JP2018011525A (ja) 2016-07-19 2018-01-25 国立大学法人大阪大学 ゲノム編集方法
WO2020100361A1 (ja) 2018-11-16 2020-05-22 国立大学法人大阪大学 ゲノム編集された細胞を製造する方法
JP2021519067A (ja) 2018-03-23 2021-08-10 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 常染色体優性疾患のための遺伝子編集
WO2021163556A1 (en) 2020-02-12 2021-08-19 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520317A (ja) 2013-05-29 2016-07-14 セレクティスＣｅｌｌｅｃｔｉｓ Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
JP2017535271A (ja) 2014-11-21 2017-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ガイドｒｎａのペアを使用したターゲティングによる遺伝子改変の方法及び組成物
JP2018011525A (ja) 2016-07-19 2018-01-25 国立大学法人大阪大学 ゲノム編集方法
JP2021519067A (ja) 2018-03-23 2021-08-10 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 常染色体優性疾患のための遺伝子編集
WO2020100361A1 (ja) 2018-11-16 2020-05-22 国立大学法人大阪大学 ゲノム編集された細胞を製造する方法
WO2021163556A1 (en) 2020-02-12 2021-08-19 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
中田慎一郎，Cas9変異体によるニックが起こす相同組換え修復様DNA組換えの分子機構の解明，科学研究費助成事業 研究成果報告書, ［online］，2020年03月30日，<URL : https://kaken.nii.ac.jp/ja/file/KAKENHI-PROJECT-16K12596/16K12596seika.pdf>，［2024年11月15日検索］，インターネット

Also Published As

Publication number Publication date
US20250129390A1 (en) 2025-04-24
WO2023054573A1 (ja) 2023-04-06
JPWO2023054573A1 (https=) 2023-04-06
EP4410975A1 (en) 2024-08-07
CN118043456A (zh) 2024-05-14
EP4410975A4 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
US20220256822A1 (en) Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes
Meier et al. Short DNA sequences inserted for gene targeting can accidentally interfere with off‐target gene expression
Ruan et al. Highly efficient CRISPR/Cas9-mediated transgene knockin at the H11 locus in pigs
EP3039145B1 (en) Efficient non-meiotic allele introgression
Demuth et al. An inducible null mutant murine model of Nijmegen breakage syndrome proves the essential function of NBS1 in chromosomal stability and cell viability
Finsterbusch et al. Alignment of homologous chromosomes and effective repair of programmed DNA double-strand breaks during mouse meiosis require the minichromosome maintenance domain containing 2 (MCMDC2) protein
US20190373865A1 (en) Genetically Modified Non-Human Animal with Human or Chimeric CTLA-4
KR20170102234A (ko) 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
Dowdle et al. Mouse BAZ1A (ACF1) is dispensable for double-strand break repair but is essential for averting improper gene expression during spermatogenesis
Thorvaldsen et al. Developmental profile of H19 differentially methylated domain (DMD) deletion alleles reveals multiple roles of the DMD in regulating allelic expression and DNA methylation at the imprinted H19/Igf2 locus
JP6958917B2 (ja) 遺伝子ノックイン細胞の作製方法
JP2022113700A (ja) ＣＲＩＳＰＲ－Ｃａｓゲノム編集に基づく、Ｆｅｌ ｄ１ノックアウト並びに関連組成物及び方法
JP6868615B2 (ja) 繁殖可能なｘｙ雌マウスを生成するための多能性細胞の選択
US20190223416A1 (en) Canine genome editing
Zhang et al. Crispr/Cas9‐mediated cleavages facilitate homologous recombination during genetic engineering of a large chromosomal region
JP7672012B2 (ja) 相同染色体の一方に特異的なｄｎａ欠失を有する細胞を製造する方法
JP7426101B2 (ja) ゲノム編集された細胞を製造する方法
EP4455282A1 (en) Method for producing genome-edited cells utilizing homologous recombination
Elrick et al. The production of 4,182 mouse lines identifies experimental and biological variables impacting Cas9-mediated mutant mouse line production
WO2021186163A1 (en) Optimised methods for cleavage of target sequences
WO2024204215A1 (ja) 相同染色体の一方のＣｏｌ７ａ遺伝子に特異的なＤＮＡ欠失を有する細胞を製造する方法
Mangerich et al. A caveat in mouse genetic engineering: ectopic gene targeting in ES cells by bidirectional extension of the homology arms of a gene replacement vector carrying human PARP-1
EP4242237A1 (en) Foki nuclease domain variant
Chen et al. Experimental and modeling demonstration of stronger population suppression by gene drive targeting doublesex from dominant female-sterile resistance alleles
Bauer et al. Female-or male-biased offspring generated by targeted distortion of sex chromosome transmission in the mouse

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250403

R150 Certificate of patent or registration of utility model

Ref document number: 7672012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350